Levetiracetam & Newer Antiepileptics

Levetiracetam has almost no drug interactions and doesn't require serum level monitoring — so what DO you need to watch for? The behavioral side effects that catch everyone off guard.

Levetiracetam (Keppra) is a broad-spectrum antiepileptic used for partial-onset, myoclonic, and primary generalized tonic-clonic seizures. Its mechanism is unique: it binds to synaptic vesicle protein SV2A, modulating neurotransmitter release rather than acting on sodium channels or GABA like older agents. This means it has minimal hepatic metabolism (renally excreted mostly unchanged), virtually no CYP450 drug interactions, and no need for routine serum drug level monitoring — a sharp contrast to phenytoin and valproic acid. Dose adjustment is required in renal impairment based on creatinine clearance. The most clinically significant adverse effects are neuropsychiatric: irritability, aggression, mood changes, and suicidal ideation. These can appear within the first few weeks. You teach the patient and family to report behavioral changes immediately. Other side effects include somnolence, dizziness, and fatigue. Levetiracetam should never be stopped abruptly — taper to avoid rebound seizures, a principle shared across all antiepileptics.

Key Distinctions

Don't confuse levetiracetam's renal clearance with phenytoin's hepatic metabolism — levetiracetam needs renal dose adjustment, not hepatic monitoring. Students assume all antiepileptics require drug level monitoring; levetiracetam does not have a standard therapeutic range checked in practice. The hallmark adverse profile is psychiatric (aggression, mood lability), not the gingival hyperplasia or hepatotoxicity seen with older agents.

Clinical Pearl

Keppra keeps it simple — no drug levels, no liver panels, no drug interactions. But watch the mood: irritability and aggression are its signature side effects.